Clinical Trial Update: Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab [Phase 4]

View source ↗

Summary

Phase 4 study evaluating Ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who are currently on high-dose eculizumab; results posted in 2024 follow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Ravulizumab (Ultomiris) (ravulizumab-cwvz)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 4 | Status: COMPLETED | Results posted: 2024-08-12